Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells

NCT04805021 | Recruiting

• 1 other identifier: RC20_0253
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 2

Brief Summary

Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused by the sometimes drastic decrease in the level of circulating factor VIII. This pathology occurs overwhelmingly in elderly subjects or, more rarely, in young women, during the postpartum period. It appears idiopathic in 50% of cases and associated, for the other cases, with underlying pathologies such as autoimmune pathologies (rheumatoid arthritis and bullous pemphigoid in particular) and neoplasias, or with a particular circumstance represented by the post -partum. The association between this autoimmune pathology and its association with pathologies of the same type or with circumstances involving the immune system, suggests that common mechanisms could favor its emergence. This study therefore proposes to study lymphocyte populations and subpopulations as well as Myeloid-Derived Suppressor Cells and the cytokine profile, which are abnormal in a large part of autoimmune pathologies.

Conditions

Hemophilia A

Outcome Measures

Primary Outcomes (1)

• Evaluate the evolution of lymphocyte populations and subpopulations, MDSCs and inflammatory cytokines in patients with hemophilia A acquired at diagnosis and during follow-up

  Comparisons between diagnosis and during follow-up

  2 years

Secondary Outcomes (3)

• To test the link between the severity of the disease at diagnosis and the cellular and cytokine parameters.

  2 years

• Comparisons of baseline lymphocyte and cytokine data between patients with a favorable versus unfavorable final diagnosis.

  2 years

• Comparison of lymphocyte populations and subpopulations, MDSCs and inflammatory cytokines between different groups.

  2 years

Study Arms (4)

Patients in the Acquired Hemophilia A group.

Other: no intervention

patients in the constitutional hemophilia A group.

Other: no intervention

patients in the control subjects group.

Other: no intervention

patients in the group of patients with inflammatory pathology.

Other: no intervention

Interventions

no intervention OTHER

no intervention

Patients in the Acquired Hemophilia A group.; patients in the constitutional hemophilia A group.; patients in the control subjects group.; patients in the group of patients with inflammatory pathology.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with acquired hemophilia A will be recruited prospectively when diagnosed with acquired hemophilia A and will be followed in the study until recovery. Patients with constitutional hemophilia A will be recruited prospectively. They should be over 50 years old and have severe or moderate hemophilia A, and not be taking any treatment that could interfere with the immune system or inflammatory markers. Population of control subjects without coagulation abnormalities, over 60 years of age and not taking any treatment likely to interfere with the immune system or inflammatory markers. Patient population with inflammatory pathology will include subjects with an inflammatory pathology likely, according to the literature, to be associated with acquired hemophilia A and, in particular patients with rheumatoid arthritis, if possible at diagnosis and not taking any treatment likely to interfere with the disease. immune system or inflammatory markers.

You may qualify if:

• Patient population with acquired hemophilia A:
• Adult patients with a diagnosis of acquired hemophilia A and with a social security system. Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
• Obtaining signed and written informed consent for biocollection consent.
• Population of Patients with constitutional hemophilia A:
• Adult patients over 50 years of age with severe or moderate constitutional hemophilia A, with no history of autoimmune disease, and with a social security system.
• Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
• Obtaining signed and written informed consent for biocollection consent.
• Population of control subjects:
• Adult patients, over the age of 60, without a coagulation abnormality, with no history of autoimmune disease, and with a social security system.
• Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
• Obtaining signed and written informed consent for biocollection consent.
• Patient population with inflammatory pathology:
• Adult patients over the age of 50 with an inflammatory pathology likely to be associated with acquired hemophilia A, and with a social security system.
• Obtaining oral non-opposition from the patient to participate in the study following the submission of an information note relating to the project.
• Obtaining signed and written informed consent for biocollection consent.

You may not qualify if:

• For the 4 groups:
• Minor patient, under guardianship or curatorship.
• Pregnant and lactating women.
• Blood transfusion less than 7 days old.

Sponsors & Collaborators

• Nantes University Hospital: lead

Study Sites (2)

CHU de Nantes

Nantes, France

RECRUITING

CH de Saint Nazaire

Saint-Nazaire, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

a tube of blood taken from CTAD or citrate

MeSH Terms

Conditions

Hemophilia A

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, Inherited; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Marc Fouassier

  Nantes University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Marc Fouassier

CONTACT

02 40 08 40 49; marc.fouassier@chu-nantes.fr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 16, 2021
• First Posted: March 18, 2021
• Study Start: November 30, 2021
• Primary Completion: June 30, 2024
• Study Completion: June 30, 2025
• Last Updated: March 21, 2024

Record last verified: 2024-03

Locations

FR (2)